Could new data lead to MDx Health (Irvine, California) pursuing an additional indication for its ConfirmMDx assay? That seems to be the question after preliminary results from a study presented at the 2014 Genitourinary Cancers Symposium 2014 in San Francisco last week, confirmed that epigenetic profiling of selected genes provides prognostic information, corresponding to Gleason score (GS), could help to identify patients with aggressive prostate cancer. Read More
